<?xml version="1.0" encoding="UTF-8"?><rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>gerçek dünya kanıtı &#8211; BIOENGINEER.ORG</title>
	<atom:link href="https://bioengineer.org/tag/gercek-dunya-kaniti/feed/" rel="self" type="application/rss+xml" />
	<link>https://bioengineer.org</link>
	<description>Bioengineering</description>
	<lastBuildDate>Sun, 04 Jan 2026 13:51:54 +0000</lastBuildDate>
	<language>en-US</language>
	<sy:updatePeriod>
	hourly	</sy:updatePeriod>
	<sy:updateFrequency>
	1	</sy:updateFrequency>
	<generator>https://wordpress.org/?v=7.0</generator>

<image>
	<url>https://bioengineer.org/wp-content/uploads/2019/09/cropped-bioengineering-32x32.png</url>
	<title>gerçek dünya kanıtı &#8211; BIOENGINEER.ORG</title>
	<link>https://bioengineer.org</link>
	<width>32</width>
	<height>32</height>
</image> 
<site xmlns="com-wordpress:feed-additions:1">72741379</site>	<item>
		<title>Romosozumab Outperforms PTH in Reducing Osteoporotic Fractures</title>
		<link>https://bioengineer.org/romosozumab-outperforms-pth-in-reducing-osteoporotic-fractures/</link>
		
		<dc:creator><![CDATA[Bioengineer]]></dc:creator>
		<pubDate>Sun, 04 Jan 2026 13:51:30 +0000</pubDate>
				<category><![CDATA[Health]]></category>
		<category><![CDATA[gerçek dünya kanıtı]]></category>
		<category><![CDATA[kadın sağlığı]]></category>
		<category><![CDATA[kırık önleme]]></category>
		<category><![CDATA[osteoporoz tedavisi]]></category>
		<category><![CDATA[romosozumab vs PTH]]></category>
		<guid isPermaLink="false">https://bioengineer.org/romosozumab-outperforms-pth-in-reducing-osteoporotic-fractures/</guid>

					<description><![CDATA[In a groundbreaking study recently published in “Biol Sex Differ,” researchers Lu, Wang, and Yang delve into the impact of romosozumab—an innovative monoclonal antibody—on osteoporotic fractures compared to conventional PTH (1–34) analogs specifically in women. This research promises a significant leap forward in our understanding of osteoporosis treatment and the optimization of fracture prevention strategies [&#8230;]]]></description>
		
		
		
		<post-id xmlns="com-wordpress:feed-additions:1">313549</post-id>	</item>
	</channel>
</rss>
